進行皮膚悪性腫瘍に対するペムブロリズマブ、二次治療以降の適応で中国で承認【米・Merck】

中国では、進行皮膚悪性腫瘍に対する抗PD-1抗体としては初の承認に

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA®, Merck’s anti-PD-1 therapy, has been approved by the China National Drug Administration (CNDA) for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy. This is the first and only approval of an anti-PD-1 therapy for advanced melanoma in China.


 


 


 

コメント

Leave a comment

Your email address will not be published.


*